Get the Stockscreener App
1.145
0.43%
-0.005
After Hours:
1.14
-0.005
-0.44%
Rein Therapeutics Inc stock is traded at $1.145, with a volume of 370.50K.
It is down -0.43% in the last 24 hours and down -17.63% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.15
Open:
$1.16
24h Volume:
370.50K
Relative Volume:
3.31
Market Cap:
$26.68M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.23%
1M Performance:
-17.63%
6M Performance:
-35.31%
1Y Performance:
+0.00%
1-Day Range:
$1.13
$1.17
1-Week Range:
$1.13
$1.25
52-Week Range:
$1.04
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.145 | 27.63M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Can trapped investors hope for a rebound in Rein Therapeutics Inc.Options Play & High Win Rate Trade Alerts - newser.com
Real time scanner hits for Rein Therapeutics Inc. explainedStop Loss & Growth Focused Investment Plans - newser.com
Sector ETF performance correlation with Rein Therapeutics Inc.Market Trend Report & Weekly High Conviction Trade Ideas - newser.com
Will Rein Therapeutics Inc. stock pay special dividendsVolume Spike & Weekly Breakout Watchlists - newser.com
Momentum divergence signals in Rein Therapeutics Inc. chartLayoff News & Expert Approved Momentum Trade Ideas - newser.com
Has Rein Therapeutics Inc. found a price floorJuly 2025 PostEarnings & Free Weekly Chart Analysis and Trade Guides - newser.com
Rein Therapeutics Inc. stock trend outlook and recovery pathWeekly Profit Summary & Weekly High Conviction Trade Ideas - newser.com
What analysts say about Rein Therapeutics Inc stockDouble Top/Bottom Patterns & Free Superior Stock Performance - earlytimes.in
What drives Rein Therapeutics Inc stock pricePrice-to-Book Ratio Updates & Reinvest for Maximum Compounding Returns - earlytimes.in
Is Rein Therapeutics Inc a good long term investmentCapital Gains Strategies & Lower Drawdowns With Smart Position Sizing - earlytimes.in
H.C. Wainwright reiterates Buy rating on Rein Therapeutics stock at $10 - Investing.com Canada
H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Raises Target Price to $10 - 富途牛牛
H.C. Wainwright initiates Rein Therapeutics stock with Buy rating on IPF treatment potential - Investing.com Canada
HC Wainwright & Co. Initiates Coverage of Rein Therapeutics (RNTX) with Buy Recommendation - Nasdaq
HC Wainwright Initiates Rein Therapeutics at Buy With $10 Price Target - MarketScreener
Is Rein Therapeutics Inc. stock ready for a breakoutQuarterly Trade Report & Community Consensus Trade Alerts - newser.com
What’s the recovery path for long term holders of Rein Therapeutics Inc.Bear Alert & Accurate Buy Signal Notifications - newser.com
Is a relief rally coming for Rein Therapeutics Inc. holdersJuly 2025 Price Swings & Expert Verified Movement Alerts - newser.com
Advanced analytics toolkit walkthrough for Rein Therapeutics Inc.July 2025 Closing Moves & Reliable Breakout Forecasts - newser.com
Using fundamentals and technicals on Rein Therapeutics Inc.Earnings Risk Report & Community Verified Swing Trade Signals - newser.com
Dow Update: Will Rein Therapeutics Inc. benefit from geopolitical trendsJuly 2025 Analyst Calls & Consistent Profit Trade Alerts - خودرو بانک
EV Market: Is Rein Therapeutics Inc stock showing strong momentumJuly 2025 Short Interest & Safe Entry Point Alerts - خودرو بانک
Stock Market Recap: Is Themes Etf Trust Leverage Shares 2x Long CRM Daily Etf part of any ETFEarnings Overview Report & AI Based Buy/Sell Signal Reports - khodrobank.com
Can Rein Therapeutics Inc sustain earnings growthQuarterly Market Review & Risk Controlled Swing Trade Alerts - khodrobank.com
Is Rein Therapeutics Inc. stock bottoming outDay Trade & Weekly Top Stock Performers List - newser.com
Rein Therapeutics reports positive data for IPF drug in patient tissue study - Investing.com Australia
Rein Therapeutics Announces Publication of New - GlobeNewswire
Trend Review: Does FORLW have a sustainable dividendWeekly Market Report & Free Technical Pattern Based Buy Signals - خودرو بانک
Will breakout in Rein Therapeutics Inc. lead to full recoveryMarket Sentiment Summary & Breakout Confirmation Trade Signals - newser.com
Visual trend scoring systems applied to Rein Therapeutics Inc.Market Sentiment Report & Daily Stock Trend Reports - newser.com
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):